文献速递临床试验与 GCP

血府逐瘀胶囊治疗气滞血瘀证:随机对照预试验研究方案

Xue-Fu-Zhu-Yu capsule in the treatment of qi stagnation and blood stasis syndrome: a study protocol for a randomised controlled pilot and feasibility trial.
PubMed 文献 · Trials · 2018-09-21

主要采用中医患者报告结局量表、单一症状体征量表和疼痛量表评估证候相关结局,并按照GCP进行质量控制。该试验旨在首次定义和优化血府逐瘀胶囊治疗气滞血瘀证的证候疗效评价指标。

要点

  • 研究聚焦气滞血瘀证候结局,而非特定疾病结局。
  • 采用中医PRO量表、症状体征量表和疼痛量表评价疗效。

核心结论

  • 该试验旨在首次定义和优化血府逐瘀胶囊治疗气滞血瘀证的证候疗效评价指标。

研究设计与样本

  • 采用随机、对照、预试验与可行性试验设计,研究周期7周。
  • 参与者从中国广安门医院、护国寺中医医院和望京医院招募。

关键数值与推荐

  • 纳入标准要求符合气滞血瘀证诊断标准。
  • 结局指标包括气滞血瘀证中医患者报告结局量表、单一症状体征量表和疼痛量表。
  • 使用临床数据管理系统(http://www.tcmcec.net/)收集和管理数据,并按照GCP进行质量控制。

临床怎么用

  • 该试验聚焦证候结局,为血府逐瘀胶囊治疗气滞血瘀证的证候疗效评价提供方法学基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Qi stagnation and blood stasis syndrome (QS&BSS) is one of the common Zhengs in traditional Chinese medicine (TCM), which manifests as various symptoms and signs, such as distending pain or a tingling sensation in a fixed position. In recent years, a number of clinical trials have focused on the effectiveness and safety of XFZYC in patients with a QS&BSS subtype disease, such as coronary heart disease, hyperlipidaemia, ischaemic cerebrovascular disease, gastritis, dysmenorrhoea, or arthritis, in terms of the outcomes of relevant diseases. However, there is lack of evidence of the effects of XFZYC in patients with QS&BSS with different diseases, focusing on the outcomes of Zhengs. METHODS/DESIGN: A randomised, controlled, pilot and feasibility trial will be employed in this study, using a 7-week study period. Participants will be recruited from Guang'anmen Hospital, Huguosi TCM Hospital, Wangjing Hospital in China. One hundred and twenty participants will be randomised to a treatment group (Xue-Fu-Zhu-Yu Capsule (XFZYC)) and placebo group in a 1:1 ratio. Participants included in the study must be diagnosed with Qi stagnation and blood stasis syndrome criteria. The outcome measurements will include the traditional Chinese medicine patient-reported outcome (PRO) scale for QS&BSS, the single symptom and sign scale of QS&BSS, and the pain scale of QS&BSS. The clinical data management system ( http://www.tcmcec.net /) will be used to collect and manage the data. Quality control will be used, according to Good Clinical Practice (GCP). DISCUSSION: Previous studies were expected to evaluate whether the addition of XFZYC to standard routine treatment would enhance the treatment effectiveness and improve the biomedical parameters pertaining to relevant disease. However, this trial is focused on the outcome of Zhengs, and we chose a range of outcome measurements to assess the improvement of relevant symptoms and signs. This trial is the first study designed to define and optimise the outcome measurements of Zhengs of XFZYC in the treatment of patients with QS&BSS. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03091634 . Registered on 12 August 2018. Release date 6 May 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. He H, Chen G, Gao J, et al. Xue-Fu-Zhu-Yu capsule in the treatment of qi stagnation and blood stasis syndrome: a study protocol for a randomised controlled pilot and feasibility trial. Trials. 2018. PMID: 30241562. doi:10.1186/s13063-018-2908-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。